Emcure expands injectables capacity, opens 3rd facility in Gujarat
时间:2024-05-18 15:03:14 阅读(143)
The third injectable facility of Emcure Pharmaceuticals in Mehsana, Gujarat, which was commissioned in August 2023, is now ready for commercial supplies to domestic and international markets. The company already has an oral formulations manufacturing line in Mehsana.
It also has a facility in Hinjawadi, Pune, with a capacity of 80.64 million vials per annum and another in Sanand, Gujarat, with a capacity to churn out 72 million vials per annum.
IPO-bound Emcure’s manufacturing operations cover oral solids, oral liquids and injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs. The company’s subsidiary Gennova Biopharmaceuticals,also plans to use its mRNA platform, through which it launched the Covid-19 vaccine, forthree other vaccines for Zoster, Zika and Rabies.
Emcure’s injectable portfolio includes complex iron injectables, oncology, steroids, suspensions and emulsions. Emcure can produce high-potency injectables, particularly oncology products.
Emcure had filed a draft red herring prospectus (DRHP) on December 16 for its Rs 800 crore IPO. It is the 12th largest Indian pharmaceutical company and the largest pharmaceutical company in the gynaecology, blood-related and HIV antiviral therapeutics segment in the country.
For the international markets, the firm’s focus is on developing and commercialising products, which requires significant expertise and is subject to less competition and offers higher margins.
In Europe and other key target markets, they are focused on higher-value-added generics and complex injectables, such as Cidofovir and Meropenem. Europe is one of the focus areas in the hospital segment, as it is a large market for complex injectables products, such as Cidofovir, BiCNU and Treprostinil, the company’s DRHP said.
The company is working on `ready-to-use’ products that reduce multi-step dose preparation and enable ease of use by physicians.
猜你喜欢
- Israel Embassy blast case- Accused used crude bomb with home-made timer, post-blast analysis finds ‘chemical explosion’
- Invesco marks up Swiggy’s valuation to $8
- Unlisted equities in MF portfolios under Sebi scanner
- USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
- Is Gold losing its sheen due to inflationary pressure-
- Divine Power Energy plans to launch IPO by March; eyes Rs 400 crore turnover by 2026
- Delhivery shares buy or sell- Even analysts disagree with each other; here are their arguments
- IRCTC, BPCL, ONGC among stocks to go ex-dividend next week; check full list here
- ITC among 67 BSE stocks to hit new 52-week high; GR Infraprojects, others at fresh 52-week lows